Bionano Genomics Posts Q2 Margin Gain
Bionano Genomics (NASDAQ:BNGO), a provider of genome mapping tools and software, released its financial results for Q2 2025 on August 14, 2025. GAAP revenue was $6.73 million, slightly ahead of analyst expectations of $6.56 million (GAAP). While this revenue figure marked a 13% decline from the same quarter last year (GAAP), gross margin (GAAP) improved significantly to 52%. Operating expenses (GAAP) were sharply lower year over year in Q2 2025, contributing to a narrower net loss. Overall, the period highlighted continued progress in cost control, stronger recurring revenue from consumables and software, and evidence that a shift in commercial strategy is starting to pay off, even as total revenue moderated.
Bionano Genomics is a life sciences company that specializes in optical genome mapping (OGM) technology, which is designed to identify large-scale structural variations in DNA that are difficult to detect with conventional gene sequencing. Its core systems, such as Saphyr and Stratys, help researchers and clinicians analyze genetic disorders, blood cancers, and rare diseases by providing a clearer and more comprehensive view of the genome.
The company’s business has increasingly centered on driving adoption among high-volume, routine users by integrating powerful software tools like VIA and Solve, alongside OGM instruments and consumables. Key factors for growth are expanding the recurring consumables and software revenue streams, supporting clinical research with robust publications, and securing progress toward regulatory reimbursement for its technology.
Source Fool.com
